L.J. Andersen

OC-0449: Pattern of failure and disease control in patients treated for glottic cancer in Denmark 1971-2011

Material and Methods: Patients diagnosed alive with a scc of the glottic larynx between 1971 and 2011 were included if curative treatment was started. Patients were identified from the DAHANCA database, and crosschecked with the National Cancer Registry. Missing information was obtained from hospitals records and the National Patient Registry. Results: A total of 5001 patients were identified. 98% of patients had primary RT. The median follow-up was 9.1 years (patients alive) and 5.7 years (patients who died). 10 patients were lost to follow-up. 1511 failures were observed; hereof 93 %, 11 % and 5 % included Tand/or Nand/or M-site, respectively. 5-year incidence of local failure (LF) and locoregional failure (LRF) was 26 % and 27%, respectively. From the 1970s to the 2000s the 5-year incidence of LF and LRF decreased significantly; 32% vs 19% and 34% vs 21%, respectively. Curative salvage was intended in 1088/1511 patients with failure, hereof 707 achieved ultimate control. In total, 980 patients had a laryngectomy, hereof 11 was primary treatment, 12 were caused by morbidity. The 5-year incidence of laryngectomy was 18%, decreasing from 26 % (1970s) to 10% (2000s). The 5-year incidence of ultimate failure was unchanged over time (range 13-16 %). 5-year estimates of laryngectomy free survival (LFS), Disease free survival(DFS) and Overall survival(OS) was 54%, 63% and 64%, respectively. LFS increased continuously, contrary to DFS and OS, which were stable in the 1970s-1990s but increased in the 2000s. LFS, DFS and OS were significantly higher in the 00s compared to the earlier decades.

OC-0149 HPV, SMOKING AND RT-OUTCOME IN ADVANCED OPC TREATED WITHOUT CHEMOTHERAPY – ANALYSIS OF DAHANCA PATIENTS

Purpose/Objective: Tumour HPV-status has major impact on radiotherapy (RT) outcome in oropharyngeal carcinoma (OPC). Likewise smoking history is known to have prognostic implications on its own. The aim of this study was to investigate the impact of HPVstatus and smoking in patients (pts) with advanced OPC treated with accelerated RT and the hypoxic cell radiosensitizer Nimorazole, but no chemotherapy. Materials and Methods: 181 pts with stage III-IV OPC and known smoking history were identified in the DAHANCA database. All pts were treated between 1992-2005 with curatively intended primary RT delivered as moderately accelerated fractionation (66-68Gy in 33-34 fx, 6fx/week) and concomitant Nimorazole. Pre-treatment tumour blocks were evaluated by immunohistochemistry for HPV-associated p16-expression (pos/neg) and smoking history was analysed as number of cumulative packyears (> or 10pckyrs (N=70) were 77%, 81% and 63% at 5 years, respectively. Essentially all pts with p16neg tumours (N=78) had a smoking history of >10pckyrs, and outcome in this group of pts was significantly worse than that of patients with p16pos tumours, regardless of packyears. See Figure 1.